Syndax Pharmaceuticals Announces Appointment of Steve Sabus as Chief Commercial Officer
Syndax Pharmaceuticals, a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, has announced the appointment of Steve Sabus to the role of Chief Commercial Officer (CCO), effective December 5, 2022. Mr. Sabus brings to Syndax more than 30 years of commercial experience launching drugs and building sales and marketing organizations within the biopharmaceutical industry. As Chief Commercial Officer, Mr. Sabus will oversee all commercial functions, including the development of critical launch initiatives, sales planning and commercial strategy.
“Steve is an accomplished executive who has launched and grown several important products within oncology, and I look forward to his contributions,” said Michael A. Metzger, Chief Executive Officer. “Steve’s leadership and operational experience, including building commercial teams and developing successful launch strategies, will be invaluable as we prepare for the potential commercialization of two first- and best-in-class therapies in oncology.”
“This is an exciting time to join Syndax, and I look forward to building a strong commercial culture and capabilities to support potential product launches in 2024,” said Mr. Sabus. “Both revumenib and axatilimab have compelling clinical profiles with meaningful market opportunities. I am eager to begin working with the team to develop a commercial strategy that realizes their full potential, with the ultimate goal of making a meaningful difference in the lives of people with cancer.”
Prior to joining Syndax, Mr. Sabus served as CCO at Turning Point Therapeutics, before being acquired by BMS. Before Turning Point Therapeutics, Mr. Sabus held senior commercial roles at Astellas Pharma for over 15 years, most recently serving as the Head of Oncology. In this role, he led development of a commercial strategy for the planned launch of zolbetuximab, expanded the market for Xtandi® by successfully launching into new indications, and steered the growth of its partnered product, Padcev®. Mr. Sabus was also responsible for growing Xospata® for acute myeloid leukemia, as well as preparing for its expansion into additional indications.
Earlier in his tenure at Astellas, Mr. Sabus headed the U.S. Medical Specialties business unit where he designed commercial strategies to extend the portfolio and increase market impact across therapeutic areas. Additionally, he was the General Manager of Astellas Canada, where his team launched Xospata®.
Companies In This Post
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more